FDA Allows Normal Saline Importation to Alleviate Shortage

A critical shortage of 0.9-percent sodium chloride injection (normal saline) that threatens patients' safety prompted the U.S. Food and Drug Administration (FDA) to allow B. Braun Medical Inc., of Bethlehem, Pa., to temporarily distribute the drug in the United States from its manufacturing facility in Germany. 

FDA will also allow importation of saline products from Baxter Healthcare Corporation's plant in Spain and Fresenius Kabi USA's plant in Norway to help fill the demand for the drug in the wake of the shortage. 

FDA reports it inspected all three manufacturers' facilities abroad to ensure they currently meet FDA standards. FDA asks health care professionals to contact the manufacturers directly to obtain their products. 

Visit FDA's drug shortage webpage for updates.

Action, Oct. 31, 2014

Last Updated On

May 12, 2016

Related Content